Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dirceu Barbano reappointed director of Brazil’s Anvisa

This article was originally published in Clinica

Executive Summary

Dirceu Barbano has been reappointed as director of Brazilian healthcare regulatory agency Anvisa for a second three-year term. The priorities for the agency during his tenure will be to make it “more efficient without compromising on the rigour that characterises its decision-making”. This will be achieved by “improving the regulatory framework [and through] closer dialogue with society”, he told the Senate’s Social Affairs Commission (CAS), which gave final approval for the appointment. Mr Barbano, a pharmacist, originally joined Anvisa in October 2008, but has been serving as the agency’s director-president since January 2011, when the health ministry was restructured under the change of federal presidency (www.clinica.co.uk, 7 January 2011).

You may also be interested in...



Singapore And Malaysia Test Joint Evaluation Of Generics

A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.

Australia Looking Into In-Vitro Self-Test Deregulation

In-vitro self-tests for influenza and sexually transmitted diseases as well as direct-to-consumer genetic tests are on the agenda for deregulation in Australia. 

ConMed’s ‘No Smoking’ Drive Has Multiple Benefits In General Surgery

ConMed Corp. is company of two halves  ̶  general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.

Topics

UsernamePublicRestriction

Register

MT097959

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel